Zentalis Pharmaceuticals Presents Clinical Data Updates
Ticker: ZNTL · Form: 8-K · Filed: Apr 17, 2026 · CIK: 0001725160
Sentiment: neutral
Topics: clinical-trial-data, drug-development, pharmaceuticals
TL;DR
Zentalis dropped new clinical data for ZN-c3 and ZN-d5, showing early results.
AI Summary
On April 17, 2026, Zentalis Pharmaceuticals, Inc. filed an 8-K report detailing updates on its clinical programs. The company presented data from its Phase 1 study of ZN-c3 in patients with advanced solid tumors, as well as data from its Phase 1/2 study of ZN-d5 in patients with solid tumors. These presentations included information on safety, tolerability, and preliminary efficacy.
Why It Matters
This filing provides investors with crucial updates on the progress and potential of Zentalis' drug candidates, impacting the company's valuation and future development trajectory.
Risk Assessment
Risk Level: medium — Clinical trial data presentations carry inherent risks related to efficacy and safety outcomes, which can significantly impact stock price.
Key Players & Entities
- Zentalis Pharmaceuticals, Inc. (company) — Filer of the 8-K report
- ZN-c3 (drug) — Drug candidate discussed in Phase 1 study
- ZN-d5 (drug) — Drug candidate discussed in Phase 1/2 study
- 2026-04-17 (date) — Filing date of the 8-K report
FAQ
What specific data was presented for ZN-c3?
The filing indicates presentations of data from a Phase 1 study of ZN-c3 in patients with advanced solid tumors, including safety, tolerability, and preliminary efficacy.
What was presented regarding ZN-d5?
Data from a Phase 1/2 study of ZN-d5 in patients with solid tumors, covering safety, tolerability, and preliminary efficacy, was presented.
What is the filing date of this 8-K report?
The filing date is April 17, 2026.
What type of report is this 8-K filing?
This is a Current Report on Form 8-K, filed under Regulation FD Disclosure.
Where is Zentalis Pharmaceuticals, Inc. located?
Zentalis Pharmaceuticals, Inc. has its business and mailing address at 10275 SCIENCE CENTER DRIVE SUITE 200 SAN DIEGO CA 92121.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 17, 2026 regarding Zentalis Pharmaceuticals, Inc. (ZNTL).